MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
41.53
+1.95
+4.93%
After Hours: 40.73 -0.8 -1.93% 18:08 02/06 EST
OPEN
40.32
PREV CLOSE
39.58
HIGH
41.80
LOW
39.55
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
90.32
52 WEEK LOW
37.95
MARKET CAP
2.23B
P/E (TTM)
-22.5547
1D
5D
1M
3M
1Y
5Y
1D
Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
Benzinga · 6d ago
Weekly Report: what happened at SLNO last week (0126-0130)?
Weekly Report · 02/02 10:33
Strategic Investment Fuels Confidence in Soleno Therapeutics’ Growth Outlook and Supports Buy Rating
TipRanks · 01/29 13:35
Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)
TipRanks · 01/29 13:15
Soleno Therapeutics to Present at Major Biotech and Healthcare Conferences
Reuters · 01/29 13:00
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and Soleno Therapeutics (SLNO)
TipRanks · 01/27 13:50
Weekly Report: what happened at SLNO last week (0119-0123)?
Weekly Report · 01/26 10:32
Soleno Therapeutics Boosts Executive Pay and Severance Benefits
Reuters · 01/26 07:52
More
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.